

**PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-  
RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS**

**Version 2.0**

**The Office of the Chief Medical Officer of Health  
Communicable Disease Control Unit**

Revised: December 2020

# TABLE OF CONTENTS

1.0.	SCOPE .....	1
2.0.	ANAPHYLAXIS .....	1
2.1.	Description.....	1
2.2.	Clinical presentation .....	1
2.3.	Assessment .....	2
3.0.	PRE- AND POST-IMMUNIZATION ASSESSMENT .....	3
3.1.	Pre-immunization.....	3
3.2.	Post-immunization.....	3
4.0.	DIFFERENTIAL DIAGNOSIS OF ANAPHYLAXIS.....	3
4.1.	Vasovagal reaction.....	3
4.2.	Anxiety / pain reaction.....	4
4.3.	Breath-holding spells .....	4
4.4.	Allergic Reaction .....	4
4.5.	Injection-site reactions.....	5
5.0.	EMERGENCY TREATMENT OF ANAPHYLAXIS .....	6
6.0.	CLIENT TRANSPORT.....	8
7.0.	RECORDS AND REPORTING .....	8
8.0.	MAINTENANCE OF EPINEPHRINE AND OTHER EMERGENCY SUPPLIES ...	8
8.1.	Aqueous epinephrine (adrenaline) .....	9
9.0.	MAINTENANCE OF IMMUNIZATION COMPETENCIES.....	10
10.0.	WORKSHEET FOR ASSESSMENT AND TREATMENT OF ANAPHYLAXIS ..	10
11.0.	REFERENCES .....	13

# PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS

---

## 1.0. SCOPE

This guide is intended to help Public Health and non-Public Health immunization providers in the prevention, mitigation, assessment and management of suspected or confirmed anaphylactic reactions in Public Health clinics, medical offices or in similar non-hospital settings.

## 2.0. ANAPHYLAXIS

### 2.1. Description

Anaphylaxis is a severe allergic reaction to a foreign substance that occurs rapidly and may be fatal in some cases.

While anaphylaxis is extremely rare, every immunization carries an associated risk of producing an anaphylactic reaction. Based on Canadian surveillance data for vaccine adverse events from 1990 to 2005, the annual rate of anaphylaxis ranges from 0.11 to 0.31 cases per 100,000 doses of vaccine distributed in Canada.

Anaphylaxis often produces signs and symptoms within minutes of exposure to an offending stimulus. Most instances begin within 30 minutes after an injection of vaccine, but some reactions might develop later.

The clinical signs usually involve multiple body systems (cutaneous, respiratory, circulatory). The symptoms of anaphylaxis are varied and, in severe cases, may progress to shock and cardiovascular collapse, characterized by, among other things, an eventual loss of consciousness.

Fatalities during anaphylaxis usually result from delay in the administration of epinephrine and from severe respiratory complications, cardiovascular complications, or both.

It is important to recognize the first signs and symptoms of anaphylaxis quickly so that treatment can be administered without delay.

### 2.2. Clinical presentation

Urticaria and angioedema are the most common manifestations of anaphylaxis. Urticaria (hives) are raised, often itchy, wheals on the surface of the skin. Angioedema is a swelling similar to urticaria, but the swelling is beneath the skin rather than on the surface. The swellings, called welts, usually occur around the eyes and lips. They may also be found on the hands, feet, and neck and in the throat.

Features of early or mild anaphylaxis may include swelling and hives at the injection site, sneezing, nasal congestion, tearing, coughing and facial flushing. These symptoms are generally associated with minimal dysfunction.

Features of moderate to severe anaphylaxis include obstructive swelling of the upper airway, hypotension and marked bronchospasm (constriction of the air passages of the lung by spasmodic contraction of the bronchial muscles).

**PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED  
ANAPHYLAXIS IN NON-HOSPITAL SETTINGS**

<b>Table 1: Frequency of occurrence of signs and symptoms of anaphylaxis</b>	
<b>Signs and symptoms</b>	<b>Approximate frequency</b>
<b>Cutaneous</b>	<b>90%</b>
Generalized urticaria (hives)and/or angioedema (welts)	85 – 90%
Flushing	45 – 55%
Pruritus (itchiness) with or without rash	2 – 5%
<b>Respiratory</b>	<b>40 – 60 %</b>
Upper airway angioedema (stridor)	50 – 60%
Dyspnea (difficulty breathing), wheeze	45 – 50%
Rhinitis (nasal congestion)	15 – 20%
<b>Dizziness, syncope (fainting), hypotension</b>	<b>30 – 35%</b>
<b>Abdominal</b>	
Nausea, vomiting, diarrhea, cramping pain	25 – 30%
<b>Miscellaneous</b>	
Headache	5 – 8%
Substernal (chest) pain	4 – 6%
Seizure	1 – 2%
<b>From: The diagnosis and management of anaphylaxis: an updated parameter. (2005). Journal of Allergy and Clinical Immunology, 115, S483-523.</b>	

### 2.3. Assessment

To assess adequately the nature of any post-immunization reaction that could be of an anaphylactic nature, it is important to assess comprehensively the various organ systems that may be implicated:

- Cardiac:
  - Level of consciousness (impairment might reflect hypoxia)
  - Pulse rate (assess for rapid, weak, irregular pulse).
  - Pallor or cyanosis around perioral area
  - Capillary refill time (if a compromise in perfusion is suspected)
  - Blood pressure, if required equipment is available
- Respiratory:
  - Hoarse cry/voice, stridor (a high-pitched noisy sound occurring during inhalation), cough, wheezing, shortness of breath or labored breathing, use of accessory muscles, etc.
  - Respiratory rate
- Cutaneous:
  - Injection site(s) redness, swelling or hives
  - Facial flushing, itching, hives or welts and their extent, angioedema, other rashes
- Gastrointestinal system:
  - nausea, vomiting, diarrhea, abdominal pain

Record full details of the assessment. The use of the “Worksheet for Assessment and Treatment of Anaphylaxis” is strongly encouraged to record observed signs and symptoms as well as evolution and treatments provided (See Section 10.0)

In general, the sooner the onset, the more rapidly evolving and severe the anaphylactic reaction.

## PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS

---

### 3.0. PRE- AND POST-IMMUNIZATION ASSESSMENT

#### 3.1. Pre-immunization

Before each immunization visit, each client should be questioned with regard to known allergies or past adverse reactions to a vaccine(s) or its components.

If a client reports having an anaphylactic reaction (or other, moderate to severe reaction that may be of allergic nature) to a previous dose (or component) of the vaccine to be administered during the visit, a recommendation from the physician providing the direct order or medical directive should be sought on how to proceed (if applicable). In the case of Public Health, the regional Medical Officer of Health (MOH) should be contacted on how to proceed. If the MOH is not available, the MOH on-call pager should be used to reach an available MOH. If no physician/MOH can be reached at that time, vaccination should be postponed until the situation can be discussed with an MOH.

#### 3.2. Post-immunization

Advise recipients of any biological product (i.e., vaccine) to remain under supervision for at least 15 minutes after immunization, regardless of whether they have had the particular product previously. Thirty minutes is a safer duration when a client has had a prior allergic reaction to the biological product or a component of the biological product. Longer periods of observation (i.e. 30 minutes or more) are appropriate if localized reaction or minor systemic symptoms occur to monitor any progression.

Routine supervision should ensure that clients remain within a short distance of the vaccinator with the instruction that they ask someone to get the nurse for them immediately if they feel unwell.

When clients choose not to remain under supervision after immunization, they (or their parent/guardian) should be informed of the signs and symptoms of anaphylaxis and instructed to obtain immediate medical attention should symptoms occur.

The risk of fainting is the most common reason to keep clients under observation.

### 4.0. DIFFERENTIAL DIAGNOSIS OF ANAPHYLAXIS

Anaphylaxis must be distinguished from fainting (vasovagal syncope), anxiety and breath-holding spells, which are more common and benign reactions.

#### 4.1. Vasovagal reaction

During a vasovagal reaction, the client suddenly becomes pale, feels dizzy and may lose consciousness and collapse. Fainting is sometimes accompanied by brief clonic seizure activity (i.e., rhythmic jerking of the limbs), but this generally requires no specific treatment or investigation. The client should be placed in a recumbent position, turned on his/her side, with slight pronation. This will help prevent aspiration and keep the airway open while the client is unconscious, especially if seizure activity is present.

Recovery of consciousness occurs within a minute or two, but clients may remain pale, diaphoretic and mildly hypotensive for several more minutes. **If unconsciousness persists**

## **PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS**

---

**for more than two to three minutes, call 911/ambulance and proceed as per emergency treatment for anaphylaxis.** Unconsciousness may reflect hypoxia.

The lack of hives, a slow, steady pulse rate and cool pale skin distinguish a vasovagal episode from anaphylaxis.

Prior to immunization, ask the client about the history of fainting with previous immunizations.

To reduce the likelihood of fainting (and the possibility of injuries), consider the following measures to lower stress in those awaiting immunization:

- seat every client prior to immunization
- maintain a comfortably cool room temperature and, if possible, with plenty of fresh air
- avoid long line-ups in mass immunization clinics
- prepare vaccine(s) out of view of recipients
- provide privacy during vaccination
- if the client is anxious and pale but remains conscious: have him or her lie down with legs slightly elevated, reassure, and apply cold wet cloth to face.

If the client was lying down, have him or her sit for a few minutes before standing.

### **4.2. Anxiety / pain reaction**

Clients experiencing an anxiety reaction may appear fearful, pale and diaphoretic and complain of lightheadedness, dizziness and numbness, as well as tingling of the face and extremities. Hyperventilation is usually evident.

If a client appears anxious, it may be helpful to have him or her re-breathe into a paper bag until symptoms subside. This technique must be used with caution and should be a last resort option to address anxiety-related hyperventilation since an anaphylactic reaction misdiagnosed as anxiety could worsen the associated hypoxia by the use of paper bag re-breathing.

### **4.3. Breath-holding spells**

Breath-holding spells occur in some young children when they are upset, crying hard, and reacting to injection pain. With breath-holding, the child is suddenly silent, but obviously agitated. Facial flushing and perioral cyanosis deepens as breath-holding continues. Some spells end with resumption of crying, but others end with a brief period of unconsciousness during which breathing resumes. Occasionally, the breath-holding spell may be accompanied by brief clonic seizure activity. Similar spells may have been observed in other circumstances. No treatment is required beyond reassurance of the child and parents.

### **4.4. Allergic Reaction**

Allergic reactions constitute a spectrum, the extreme end of which is anaphylaxis, but milder forms may involve both the dermatologic/mucosal (e.g., urticaria, pruritus, rhinitis) and/or the respiratory systems (e.g., sneezing, rhinorrhea, etc.). Anaphylaxis is set apart from simple allergic reactions by the simultaneous involvement of the cardiovascular system and loss of intravascular volume as well as respiratory obstruction.

**PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED  
ANAPHYLAXIS IN NON-HOSPITAL SETTINGS**

---

**4.5. Injection-site reactions**

A mild local reaction resolving by itself within a few minutes does not require special observation.

If swelling and hives occur at the injection site(s):

- Keep the client under **direct observation** for at least 30 minutes to ensure the reaction remains localized
- Observe for any deterioration in condition
- If hives or swelling disappears, or there is no evidence of any progression to other parts of the body or any other symptoms within the 30-minute observation period, no further observation is necessary. Release the client from observation.
- **If any other symptoms arise**, even if considered mild (e.g., sneezing, nasal congestion, tearing, coughing, facial flushing) or if there is evidence of any progression of the hives or swelling to other parts of the body, **administer epinephrine**.
- There is little risk to the precautionary use of epinephrine, whereas delay in its administration (when required) may result in difficulty to treat anaphylaxis and eventual death
- Apply ice for comfort.

The following table provides a comparison of the key features of anaphylaxis, vasovagal reactions and anxiety reactions:

	<b>ANAPHYLAXIS</b>	<b>VASOVAGAL</b>	<b>ANXIETY</b>
<b>DEFINITION</b>	An acute systemic and potentially fatal allergic reaction to a foreign substance. IgE-mediated antibody induces histamine release from tissue mast cells.	A temporary unconsciousness caused by diminished blood supply to the brain due to painful stimuli or emotional reaction.	A protective physiological state recognized as fear, apprehension, or worry.
<b>ONSET</b>	Usually slower, most instances begin within 30 minutes after immunization.	Sudden, occurs before, during, or shortly after immunization; recovery occurs within one to two minutes	Sudden, occurs before, during, or shortly after immunization; recovery occurs within one to two minutes
<b>SKIN</b>	<ul style="list-style-type: none"> <li>• warm, clammy and flushed</li> <li>• pruritus and urticaria (&gt;90% of cases)</li> <li>• progressive, painless swelling (face, mouth and tongue)</li> </ul>	<ul style="list-style-type: none"> <li>• pale</li> <li>• excessive perspiration</li> <li>• cold, clammy</li> </ul>	<ul style="list-style-type: none"> <li>• pale</li> <li>• excessive perspiration</li> <li>• cold, clammy</li> </ul>
<b>BREATHING</b>	<ul style="list-style-type: none"> <li>• sneezing, coughing, wheezing, labored breathing</li> <li>• upper airway swelling (hoarseness and/or difficulty swallowing) possibly causing airway</li> </ul>	<ul style="list-style-type: none"> <li>• normal or shallow, irregular, labored</li> </ul>	<ul style="list-style-type: none"> <li>• rapid and shallow (hyperventilation)</li> </ul>

**PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS**

	obstruction		
<b>PULSE</b>	<ul style="list-style-type: none"> <li>• rapid, weak, irregular</li> </ul>	<ul style="list-style-type: none"> <li>• slow, steady</li> </ul>	<ul style="list-style-type: none"> <li>• rapid</li> </ul>
<b>BLOOD PRESSURE</b>	<ul style="list-style-type: none"> <li>• hypotension which may progress to shock and collapse</li> </ul>	<ul style="list-style-type: none"> <li>• decreased systolic and diastolic</li> </ul>	<ul style="list-style-type: none"> <li>• normal or elevated systolic</li> </ul>
<b>SYMPTOMS and BEHAVIOURS</b>	<ul style="list-style-type: none"> <li>• uneasiness, restlessness, agitation</li> <li>• not all signs/symptoms will be exhibited in each person; usually one body system predominates.</li> </ul>	<ul style="list-style-type: none"> <li>• fearfulness</li> <li>• light-headedness</li> <li>• dizziness</li> <li>• numbness, weakness</li> <li>• sometimes accompanied by brief clonic seizure activity</li> </ul>	<ul style="list-style-type: none"> <li>• fearfulness</li> <li>• light-headedness, dizziness</li> <li>• numbness, weakness</li> <li>• tingling around lips and spasm in the hands and feet</li> <li>• hyperventilation</li> </ul>
<b>GASTRO-INTESTINAL</b>	<ul style="list-style-type: none"> <li>• nausea and vomiting</li> <li>• abdominal pain, diarrhea</li> </ul>	<ul style="list-style-type: none"> <li>• - nausea</li> </ul>	<ul style="list-style-type: none"> <li>• - nausea</li> </ul>
<b>OTHER SYMPTOMS</b>	<ul style="list-style-type: none"> <li>• loss of consciousness</li> <li>• progression of injection site reaction beyond hives and swelling</li> </ul>	<ul style="list-style-type: none"> <li>• Loss of consciousness is possible; of short duration (one to two minutes)</li> </ul>	<ul style="list-style-type: none"> <li>• loss of consciousness in severe cases; of short duration</li> </ul>

**5.0. EMERGENCY TREATMENT OF ANAPHYLAXIS**

1. Call for assistance. Call 911 / ambulance. Do not leave the client under any circumstances.
2. Position the client in the recumbent position and elevate legs, as tolerated symptomatically. This slows progression of circulatory compromise, if present, by preventing orthostatic hypotension and helping to divert effective circulation from the periphery to the head, heart and kidneys.
3. Administer aqueous epinephrine (1:1,000) IM or SC into an unimmunized limb **immediately**.

<b>Dose: 0.01ml/kg to maximum of 0.5ml</b>	
<b>OR:</b>	
2 – 6 months	0.07 ml
7 – 12 months	0.10 ml
13 months – 4 years	0.15 ml
5 years	0.20 ml
6 – 9 years	0.30 ml
10 – 13 years	0.40 ml
≥ 14 years	0.50 ml

The most important step in the management of anaphylaxis is the immediate administration of aqueous epinephrine 1:1,000. **Failure to use epinephrine promptly is more dangerous than its improper use. There is no contraindication to epinephrine administration in anaphylaxis.**

IM injection of epinephrine into the thigh is the preferred route for administration.

DO NOT inject epinephrine into the same muscle mass (e.g., thigh) as the vaccine was administered (this may increase blood flow locally, thereby increasing absorption of the agent).



## PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS

---

If both thighs were used for immunization:

- give epinephrine IM into deltoid if client is > 12 months old
- give epinephrine SC into upper outer triceps area of the arm(s) if the client is < 12 months old

If both thighs and both arms were used for IM immunizations, give epinephrine **SC** into upper outer triceps area of the arm(s) or into the fatty area of the anterolateral thigh.

Injection of epinephrine can be made through clothing, if necessary.

**Note:** An epinephrine self-injector (Epipen or Twinject) can also be used in the situation when the immunization-provider is not present and if the layperson who administers the self-injector is knowledgeable about proper use. The regular preparations contain 0.3mL of epinephrine 1:1,000 and can be used for individuals older than six.

If a client or his or her parent/guardian refuses the administration of epinephrine when it is indicated, inform them of the risk and immediately call 911 or an ambulance to arrange for transfer to an acute-care facility. The administration of diphenhydramine hydrochloride (Benadryl) is not appropriate in this situation. Diphenhydramine hydrochloride should not administered in the treatment of anaphylaxis.

4. Previously, Benadryl was indicated as an adjunct to Epinephrine in anaphylaxis. Diphenhydramine (Benadryl) is NOT INDICATED in anaphylaxis. Antihistamines are not indicated as initial first line treatment in the emergency management of anaphylaxis as there is no effect on respiratory or cardiovascular symptoms and they are of little clinical importance in life-threatening anaphylaxis based on current evidence. H1 antihistamines (e.g. Benadryl) relieve localized and less severe systemic allergic reactions and the only useful clinical effect is the improvement of itch and hives.<sup>4, 13, 14</sup>
5. After administration of epinephrine, monitor and document vital signs (pulse, respiration, level of consciousness and blood pressure (if possible)) and reassess the client frequently until transport to the hospital.
  - If the client experiences respiratory difficulty: elevate head and chest slightly.
  - If airway is impaired: improve position by using head tilt, chin lift, or jaw thrust.
  - If vomiting is likely: turn the client to side-lying position.

Age	Heart (pulse) rate per minute, upper limit	Respiratory rate per minute, upper limit
0-1 mo	180	60
2-12 mo	160	50
12-24 mo	140	40
2-6 y	120	30
6-12 y	110	20
>12 y (adult)	100	20

From: Emergency Medicine: A comprehensive study guide. 6th edition. (2004). McGraw Hill.

6. Repeat dosing of epinephrine: If major symptoms (i.e., breathing difficulties, level of consciousness, etc.) do not improve or worsen after the first dose, additional doses of epinephrine are warranted.

## PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS

---

- Repeat epinephrine twice at five-minute intervals, as needed (maximum: three doses)
- Alternate right and left thigh or arm sites for repeat doses of epinephrine (to maximize absorption of epinephrine).

### 6.0. CLIENT TRANSPORT

Transfer the client to a hospital as quickly as possible once the first aid procedures were performed. Because 20 per cent of anaphylaxis episodes follow a biphasic course with recurrence of the reaction after a two- to nine-hour asymptomatic period, hospitalization or a long period of observation is recommended for monitoring.

### 7.0. RECORDS AND REPORTING

Document the administration of epinephrine and diphenhydramine hydrochloride. The “Worksheet for Assessment and Treatment of Anaphylaxis” (Section 10.0) can be used as an interim record for data collection before entry of the information into the Client Service Delivery System (CSDS – Public Health IT system). **Do not** send this form to the provincial Communicable Disease Control Unit (CDC Unit). Report the case of anaphylaxis under the CSDS “Adverse Events Tab.” Record the signs and symptoms in the comments field.

The use of the worksheet by all immunizers is **strongly encouraged** since it facilitates complete assessment and documentation of signs, symptoms and care provided. This will also facilitate Adverse Event Following Immunization (AEFI) reporting and the assessment of follow-up evaluations as required.

A detailed record of the incident using the New Brunswick AEFI reporting form should be completed by the immunization-provider and submitted to the local Public Health office (or, in the case of Public Health immunizers, directly to the MOH) for review and recommendations on future vaccinations. Record the MOH recommendations (i.e., contraindications, precautions, vaccination in controlled setting, etc.) in the client’s personal and electronic immunization record. Also, ensure the MOH recommendations are shared with the client.

### 8.0. MAINTENANCE OF EPINEPHRINE AND OTHER EMERGENCY SUPPLIES

Check epinephrine vials and other emergency supplies prior to each immunization clinic or at least once a month and replace if outdated.

Protect epinephrine from light and open vial(s) only when ready to use.

Do not pre-load a syringe with epinephrine in anticipation of a reaction. Epinephrine rapidly deteriorates and loses potency when exposed to oxygen.

**Suggested** anaphylaxis kit contents:

- A copy of this guideline and “Worksheet for Assessment and Treatment of Anaphylaxis”
- 3 x 1 mL ampoules of epinephrine 1:1,000 aqueous solution (within expiration time frame)
- 3- 1 cc syringes and needles (25 – 27 gauge, 1" needle)
- 3- 1cc syringe and needle (25 – 27 gauge, 1 ½" needle)
- 2- 1cc syringes and needles (25 – 27 gauge, 5/8") for SC route
- Extra needles
- A pocket mask with one-way valve

## PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS

---

- Bag valve mask (“Ambu bag”) (optional)
- Alcohol swabs
- Pens/paper
- Sphygmomanometer (optional)
- Stethoscope (optional)
- Up-to-date contact info for an Immunization Coordinator, the regional MOH as well as the MOH on-call pager

### 8.1. Aqueous epinephrine (adrenaline)

#### Action of epinephrine

- Counteracts the histamine-induced vasodilation
- Increases heart rate and cardiac contractility to increase oxygenated blood flow to vital organs
- Acts on smooth muscles of bronchial tree thereby reducing bronchospasm
- Suppresses body's immune response (slows down histamine cascade).

#### Composition

Each 1 mL dose of aqueous epinephrine 1:1,000 contains:

- 1 mg of epinephrine hydrochloride dissolved in a isotonic sodium chloride solution

#### Supply

1 mL ampoule of clear liquid

#### Storage

- Keep in the manufacturer's box at room temperature of 15° to 30°C
- Avoid exposure to light
- Do not refrigerate
- Do not freeze
- Do not administer this product if it has a pinkish or darker than slightly yellow colour or contain a precipitate
- Do not use after expiration date

#### Indications

Severe immediate hypersensitivity reaction to immunizing products

#### Contraindication

There is no contraindication in the event of anaphylaxis.

#### Precautions

In case of complication related to the first dose of epinephrine (e.g., cardiac arrhythmia, angina, hypertension), do not repeat the dose unless the benefits outweigh the risks.

**PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED  
ANAPHYLAXIS IN NON-HOSPITAL SETTINGS**

---

Clients taking beta-blockers may have a reduced response to epinephrine. However, the anaphylaxis management protocol should be applied without modification. The appropriate treatment will be administered at the hospital.

**Adverse reactions following administration of epinephrine**

Excessive doses of epinephrine may cause palpitations, tachycardia and sudden increase of blood pressure, nausea, vomiting and headache. More serious reactions are more likely to occur in clients in poor health. Although unpleasant, such effects are transient. Cardiac dysrhythmias may occur in older adults, but they are rare in otherwise healthy children.

**9.0. MAINTENANCE OF IMMUNIZATION COMPETENCIES**

All healthcare professionals involved in immunization should be able to demonstrate competence, understanding, clinical skills and current evidence-based knowledge on anaphylaxis recognition and management. Competency in anaphylaxis management is an individual professional responsibility and is guided by professional practice standards, employer policy(s) and evidence-based research.

It is strongly recommended by the Office of the Chief Medical Officer of Health that all healthcare professionals who immunize, undertake specific immunization training as outlined in the Public Health Agency of Canada Immunization Competencies for healthcare professionals (dated November 2008) before administering vaccines and biological products. This program is intended to help healthcare professionals to fulfill their roles as vaccine-providers and to ensure safe and competent immunization practice.

It is also recommended that all vaccine-providers maintain their competencies and ongoing education regarding current anaphylaxis treatment practices through refresher courses each year.

**10.0. WORKSHEET FOR ASSESSMENT AND TREATMENT OF ANAPHYLAXIS**

This form is strongly encouraged to be used to document each suspected case of anaphylaxis following administration of vaccine(s).

<b>Client Information</b>	
Client Name: _____ <i>Surname / Given Name</i>	Birth Date: ____/____/____ Medicare #: _____ <i>dd / mm / yyyy</i>
Parent / Gardian: _____	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female Telephone: _____

<b>Vaccine Information</b>				
Vaccine(s) administered	Dose	Route	Site	Lot Number

**PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS**

Date of vaccination: ____/____/____ Approximate time of administration: _____ <i>dd/mm/yyyy</i>			
Vaccine administered by _____ Contact information: _____			

<b>Client History</b>							
Asthmatic under regular medical treatment:	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(give details of severity / medications)
Eczema:	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	
History of allergies to any vaccine component(s):	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(give details of components / reaction)
History of allergies in immediate family:	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(list and give details)
History of anaphylaxis in client:	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(give details of reaction)
History of anaphylaxis in family:	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(give details of reaction / relationship)
Prior severe reactions to any vaccines:	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(give details of reaction / vaccine(s))
Current medications:	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(list)
Recent or concurrent infections:	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(give details of infection)
Recent or concurrent relevant non-infectious illness or medical condition(s):	<input type="checkbox"/>	Unknown	<input type="checkbox"/>	No	<input type="checkbox"/>	Yes	(give details of illness / condition)
Additional details:							
Client's past immunization history:							

<p><b>Assessment and care provided</b></p> <p>Initial vital signs (if recorded):</p> <p>BP: _____ Pulse: _____ Resp.: _____ Temp: _____</p> <p>When were vital signs taken in relation to the time of the reaction and treatment?</p> <p>_____</p> <p>Indicate approximate time of onset of symptoms: _____</p>
---

<p><b><u>Indicate all signs and symptoms exhibited by the client:</u></b></p> <p><b>Dermatologic or mucosal (<i>check all that apply</i>):</b></p> <p><input type="checkbox"/> Generalized erythema                      <input checked="" type="checkbox"/> Red and itchy eyes</p> <p><input type="checkbox"/> Angioedema:                      <input type="checkbox"/> generalized                      or                      <input type="checkbox"/> localized</p>
---

**PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS**

<input type="checkbox"/> Urticaria (hives):	<input type="checkbox"/> generalized	or	<input type="checkbox"/> localized at injection site
<input type="checkbox"/> Generalized pruritus:	<input type="checkbox"/> with skin rash	or	<input type="checkbox"/> without skin rash
<input type="checkbox"/> Tingling or prickle sensation:	<input type="checkbox"/> generalized	or	<input type="checkbox"/> around the mouth or limbs

**Cardiovascular (check all that apply):**

<input type="checkbox"/> Measured hypotension	<input type="checkbox"/> dizziness	<input type="checkbox"/> syncope
<input type="checkbox"/> Reduced peripheral circulation (at least 2 of the following):		
<input type="checkbox"/> Tachycardia	<input type="checkbox"/> Capillary refill time >3 seconds without hypotension	<input type="checkbox"/> Decreased level of consciousness
<input type="checkbox"/> Uncompensated shock (at least 3 of the following):		
<input type="checkbox"/> Tachycardia	<input type="checkbox"/> Capillary refill time >3 seconds	
<input type="checkbox"/> Reduced central pulse volume	<input type="checkbox"/> Decreased level of consciousness	

**Respiratory (check all that apply):**

<input type="checkbox"/> Bilateral wheeze (bronchospasm)	
<input type="checkbox"/> Persistent dry cough	
<input type="checkbox"/> Stridor	
<input type="checkbox"/> Hoarse voice	
<input type="checkbox"/> Sensation of throat closure	
<input type="checkbox"/> Sneezing, rhinorrhea	
<input type="checkbox"/> rapid respiratory rate	
<input type="checkbox"/> Upper airway swelling (lip, tongue, throat, uvula, larynx)	
<input type="checkbox"/> Difficulty breathing (without wheeze or stridor)	
<input type="checkbox"/> Respiratory distress (at least 2 of the following):	
<input type="checkbox"/> Tachypnoea	<input type="checkbox"/> Increased use of accessory respiratory muscles
<input type="checkbox"/> Cyanosis	<input type="checkbox"/> Grunting

**Gastrointestinal (check all that apply):**

<input type="checkbox"/> Diarrhea	<input type="checkbox"/> Nausea	<input type="checkbox"/> Abdominal pain	<input type="checkbox"/> Vomiting
Other (please specify): _____			

<b>Medical administration</b>				
Pulse _____ Resp _____ <b>Epinephrine #1</b> Time: _____ Lot# _____	Dose:	Route	Site:	Signature of provider:
Pulse _____ Resp _____ <b>Epinephrine #2</b> Time: _____ Lot# _____	Dose:	Route:	Site:	Signature of provider:
Pulse _____ Resp _____ <b>Epinephrine #3</b> Time: _____ Lot# _____	Dose:	Route:	Site:	Signature of provider:
Attended by paramedics: <input type="checkbox"/> No <input type="checkbox"/> Yes      Transfer to hospital: <input type="checkbox"/> No <input type="checkbox"/> Yes Time of transfer to hospital/release to paramedics: _____  Released to care of family: <input type="checkbox"/> No <input type="checkbox"/> Yes Time of release to family: _____				

## PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS

Released to care of GP: \_\_\_\_\_  No  Yes

Time of release to GP: \_\_\_\_\_

**\*\*Please ensure a copy of any additional assessment and care notes are attached to this document.**

Name(s) of recorder(s): \_\_\_\_\_ Signature(s): \_\_\_\_\_

Date: \_\_\_\_\_

### 11.0. REFERENCES

American Academy of Pediatrics. (2006). Red Book: Report of the committee on infectious diseases. (27th ed.). Elk Grove Village, IL

British Columbia Communicable Disease Control Immunization Manual. Anaphylaxis Section. February 2009.

Brown, S.G.A., Mullins, R.J., & Gold, M.S. (2006). Anaphylaxis: diagnosis and management. MJA Practice Essentials – Allergy. 185, (5) 283 – 289.

BC: Anaphylaxis: Initial Emergency Treatment by Nurses (Adult & Pediatric) Clinical Decision Support Tool:

[http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Immunization/Vaccine%20Info/Anaphylaxis-Provincial DST.pdf](http://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Immunization/Vaccine%20Info/Anaphylaxis-Provincial_DST.pdf)

Canadian Immunization Guide, seventh edition- 2006

Centers for Disease Control and Prevention. (2006). General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices. *Morbidity and Mortality Weekly Report*, 55 (RR-15), 1-48.

Gorman J et al. The effect of successful treatment on the emotional and physiological response to carbon dioxide inhalation in patients with panic disorder. *Biol Psychiatry* 2004, 56(11): 862-867

Ellis, A.K. & Day, J.H. (2000). Anaphylaxis: diagnosis and treatment. *Allergy Asthma*, 23-25.

Johnson, R.F., & Peebles, R.S. (2004). Anaphylactic shock: pathophysiology, recognition, and treatment. *Seminars in Respiratory and Critical Care Medicine*, 25 (6), 695-703.

Joint Task Force on Practice Parameters: American Academy of Asthma Allergy and Immunology; American College of Allergy Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. (2005). The diagnosis and management of anaphylaxis: an updated parameter. *Journal of Allergy and Clinical Immunology*, 115, S483-523.

National Advisory Committee on Immunization. (2006). Canadian Immunization Guide. (7th ed.). Ottawa, Ontario. Public Health Agency of Canada. Available at: <http://www.phac-aspc.gc.ca/naci-ccni/index-eng.php> and <http://www.phac-aspc.gc.ca/naci-ccni/index-eng.php> Guide Errata and Clarifications, March 2008

Lieberman, P. (2003). Use of epinephrine in the treatment of anaphylaxis. *Current Opinion in*

## PROTOCOL FOR THE MANAGEMENT OF IMMUNIZATION-RELATED ANAPHYLAXIS IN NON-HOSPITAL SETTINGS

---

*Allergy and Clinical Immunology*, 3, 313-318.

Lieberman, P. (2006). Anaphylaxis. *The Medical Clinics of North America*. 90 (2006), 77-95.

Rüggeberg, J.U., Gold, M. S., Bayas, J. M., Blum, M. D., Bonhoeffer, J., Friedlander, S., Brito, G., Heininger, U., Imoukhuede, B., Khamesipour, A., Erlewyn-Lajeunesse, M., Martin, S., Mäkelä, M., Nell, P., Pool, V., Simpson, N., and The Brighton Collaboration Anaphylaxis Working Group. (2007). Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*, 25, (31), 5675 - 5684. Available at <http://www.sciencedirect.com/science>: Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data

Sampson, H. A. (2006). Second symposium on the definition and management of anaphylaxis: Summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium. *Annals of Emergency Medicine*. 47 (4), 373-380.

Simons, F.E.R., Gu, X., Simons, K.J. (2001). Epinephrine absorption in adults: intramuscular versus subcutaneous injection. *Journal of Allergy and Clinical Immunology*, 108, 871-873.

Simons, F.E. R., Roberts, J.R., Gu, X., & Simons, K.J. (1998). Epinephrine absorption in children with a history of anaphylaxis. *Journal of Allergy and Clinical Immunology*, 101, 33-37.

Thibodeau, J.L. (1993). Office management of childhood vaccine-related anaphylaxis. *Canadian Family Physician*, 40, 1602 – 1610.

Tintinalli, J.E., Kelen, G. D., Stapczynski, J.S., Ma, O.J., & Cline, D.M. (2004). *Emergency Medicine: A Comprehensive Study Guide*. (6th ed.). New York, NY: McGraw-Hill.